PathAI announces results showing reliability of NASH scoring

By staff writers

November 16, 2021 -- PathAI presented results on the concordance among pathologists and two independent panels in scoring nonalcoholic steatohepatitis (NASH) features at the 2021 American Association for the Study of Liver Diseases annual meeting.

Specifically, the study demonstrated that panel scoring can support the reproducibility of NASH scoring and reduce bias, as demonstrated in biopsies obtained in a phase III clinical trial, according to PathAI.

The pilot study was based on data from the phase III trial and assessed the concordance of NASH histology scoring as measured by the kappa statistic within a panel of three hepatopathologists and between two independent panels. The hepatopathologists were trained on NASH Clinical Research Network (CRN) scoring.

Within each panel, scores were highly concordant for all components of the NASH CRN scoring system and highest for steatosis, according to the company.

PathAI partners with Roche for AI tech
PathAI and Roche are partnering to develop and distribute PathAI's artificial intelligence (AI)-powered technology through Roche's uPath enterprise software.
PathAI, Summit Clinical partner for NASH trial services
PathAI recently entered a partnership with Summit Clinical Research that will launch a clinical trial services solution for developers of drugs to treat...
PathAI buys Poplar Healthcare
Pathology artificial intelligence software developer PathAI has purchased Poplar, the management service organization of Poplar Healthcare, an anatomic...
PathAI reports algorithm on par in PD-L1 immunotherapy studies
PathAI reported that its pathology artificial intelligence algorithm performed on par or better than board-certified pathologists in retrospective immunotherapy...
Pathology AI developer PathAI raises $60M
Pathology artificial intelligence (AI) software developer PathAI has raised $60 million in a series B funding round.

Copyright © 2021

Last Updated np 11/22/2021 5:59:00 PM